Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. - Wikidata - awgldk - TriplyDB

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.

http://www.wikidata.org/entity/Q40318856

about

Radiotherapy for advanced-stage aggressive non-Hodgkin lymphoma Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?Rituximab: mechanism of action A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma Chemotherapy combinations with monoclonal antibodies in non-Hodgkin's lymphoma Onco-miR-155 targets SHIP1 to promote TNFalpha-dependent growth of B cell lymphomas Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers 14-3-3zeta mediates resistance of diffuse large B cell lymphoma to an anthracycline-based chemotherapeutic regimen Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developments Next-generation prognostic assessment for diffuse large B-cell lymphoma Treatment of diffuse large B cell lymphoma Role of microRNA deregulation in the pathogenesis of diffuse large B-cell lymphoma (DLBCL)Rituximab treatment strategy for patients with diffuse large B-cell lymphoma after first-line therapy: a systematic review and meta-analysis Targeting CD19 in B-cell lymphoma: emerging role of SAR3419 Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary Homozygous A polymorphism of the complement C1qA276 correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549)Role of Maintenance Rituximab (Rituxan) Therapy In the Treatment of Follicular Lymphoma Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents.Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.Comparative RNA-Seq and microarray analysis of gene expression changes in B-cell lymphomas of Canis familiaris.Inference about the expected performance of a data-driven dynamic treatment regime.Primary breast lymphoma: patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network study.High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351.Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects.An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study.Phase II study of sorafenib in patients with relapsed or refractory lymphoma.Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma.Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.Severe and fatal adverse events risk associated with rituximab addition to B-cell non-Hodgkin's lymphoma (B-NHL) chemotherapy: a meta-analysis.NHL (diffuse large B cell lymphoma)Gemcitabine-(5'-phosphoramidate)-[anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549)Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP).The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression.Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?

P2860

Q24187708-2CDEFBF7-09D5-4E66-BF49-A0978EF4BB85 Q24597424-154EACB3-949A-4815-912D-FD14C4F5D4FE Q24607358-81EB57CC-8251-452F-872F-6E70DCBDF77E Q24607479-8EF2E2C3-4E8E-4FD2-A073-21804A07E83F Q24633714-CC40DD9E-CFE2-4BCB-BF9D-81626E1E88FC Q24645617-37D5C9BA-E261-4AE4-8521-20CE2544DC53 Q24646379-95499339-CBFC-41FD-AABF-3A20A840C70F Q24658236-2C5668E5-CEA4-45D1-9DBD-EE7774D10A70 Q26775442-31F8D610-4CA4-4687-9CAC-7212B29BC978 Q26796428-7D132A0C-F3BD-4A8D-A0EB-1BB20C308F2B Q27006062-073D6BA4-DDB6-414A-9136-2725CE06FE51 Q27016561-381F61D9-0317-4951-A332-5C186777000C Q27025272-4930F63D-41C3-414C-BE0E-3F8E9688B93A Q27027562-856750F4-2AE0-4F4C-9508-396BBFA10DCC Q28088365-00325139-F41D-4740-9231-C5221C831F14 Q28389577-3C4BAEC0-9450-4B75-9C5D-C2A3BCA5D4FB Q28390181-54AA4EE6-ACE0-4EBA-AF55-17F0EBBA4DA7 Q28829762-9716A100-331B-458B-8BC0-69AFDCAF673C Q28972464-066BFCB0-31EC-4798-A746-784D3778DE12 Q30249335-B32DF7C7-6903-46C5-A9DE-E15014C27E1D Q30275206-5A9730E8-ADCE-40B3-A382-C2AC9E3672D2 Q30455450-FE79ACC0-499D-4841-9DCA-549F0BA6FAB2 Q30830842-7594AA2F-5089-4024-8688-EFA88C9E57CC Q33326473-43792804-2EC2-4B78-B51F-CBA675E75D2A Q33375173-ABDB62B6-8CB2-413D-9178-45B89CEC396C Q33388543-97388489-F89D-4FA8-A854-FFAF9D636ABF Q33393623-C28B8E5D-2428-410B-A64B-6B6046ECD717 Q33396036-D596CBFE-67EA-46F4-8A7E-D8EED33595EB Q33401136-2AC03904-7341-4621-BFE2-851FC6E98BEB Q33402203-3BB221AA-A9D2-4F69-A4ED-5B6210CD3FEC Q33406444-D8F83D4D-4797-43F6-BF2D-0074821F9ADF Q33406742-90A8F5A9-A795-44A3-9144-0674E0AB5FB8 Q33408772-D4A832CC-F8E6-4F10-B0FC-AB822D2A2A2B Q33415880-124AE639-07B0-4E1A-AED1-080E896BAC52 Q33421964-E406544E-DC06-481F-9697-ECC2E062D729 Q33446735-A92A3FC2-B321-4F17-A984-36F3E59986AD Q33578254-C31F5C15-D90B-4152-BA69-D64F3019C929 Q33601693-F79AFE67-8685-4D85-BC32-26F792A91700 Q33616251-996885C0-29EF-4D0A-83C7-4F5F91F86B54 Q33622342-FC276C7D-FC66-4858-9F7B-3B4653A93775

P2860

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.

http://www.wikidata.org/entity/Q40318856

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Rituximab-CHOP versus CHOP alo ...... diffuse large B-cell lymphoma.

@en

type

label

Rituximab-CHOP versus CHOP alo ...... diffuse large B-cell lymphoma.

@en

prefLabel

Rituximab-CHOP versus CHOP alo ...... diffuse large B-cell lymphoma.

@en

P1433

Q40318856-A7E1E422-5DF3-46BC-875D-3FD3AB140F26

P1476

Q40318856-9244B19A-915C-426E-8E60-4576A4AD4A57

P2093

Q40318856-3BEE7BF7-6DCD-46C6-8217-2E7CF4D31B9E

Q40318856-3FB269DA-1AF1-427E-B242-5B90209CFD9C

Q40318856-756056E5-E7BF-4E8F-93FB-009E04F151D7

Q40318856-8734C360-55C4-4377-87DF-58B43EF3E54A

Q40318856-8CD32682-A0E4-4933-B910-042962C90D13

Q40318856-B796B732-DD70-4F28-A532-4F385E8F5F43

Q40318856-C0949C5B-10A2-480E-8678-3E2064EFB50A

Q40318856-D423BF75-7098-4D51-B0B4-1843E98591A5

Q40318856-E6FAD4C0-31B2-4F6D-ACAD-BB5C1EEBC287

Q40318856-F3559AF6-6913-49F1-ABF5-5A565172EA7F

P304

Q40318856-986246A7-5215-477F-B9CA-37E2F783B659

P31

Q40318856-D9C97398-B517-4329-B623-42333BAAC016

P356

Q40318856-F33C625D-E35E-42C7-830C-28CB36790222

P407

Q40318856-E931E45C-32DC-40EC-B37E-9F18444B366B

P433

Q40318856-9BC90BD6-94C1-4FD3-9652-D8A5DA74CA88

P478

Q40318856-A32335FD-F98F-4FCB-9B10-E771BE5AF721

P50

Q40318856-3D03E69A-8969-473D-AA1C-1D4F5349E6A6

P577

Q40318856-942A20F1-FF4D-40F0-BA22-C9D8FA2B70F5

P698

Q40318856-2FE13CD0-8339-4E71-B8E3-87BC2C0FA9AB

P356

JCO.2005.05.1003

P1433

Journal of Clinical Oncology

P1476

Rituximab-CHOP versus CHOP alo ...... diffuse large B-cell lymphoma.

@en

P2093

Bruce A Peterson

http://www.w3.org/2001/XMLSchema#string

Bruce Woda

http://www.w3.org/2001/XMLSchema#string

Edie A Weller

http://www.w3.org/2001/XMLSchema#string

Jeffrey B Cohn

http://www.w3.org/2001/XMLSchema#string

Peter A Cassileth

http://www.w3.org/2001/XMLSchema#string

Richard I Fisher

http://www.w3.org/2001/XMLSchema#string

Sandra J Horning

http://www.w3.org/2001/XMLSchema#string

Shaker R Dakhil

http://www.w3.org/2001/XMLSchema#string

Thomas M Habermann

http://www.w3.org/2001/XMLSchema#string

Vicki A Morrison

http://www.w3.org/2001/XMLSchema#string

P304

3121-3127

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.05.1003

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Randy D Gascoyne

P577

2006-06-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16754935

http://www.w3.org/2001/XMLSchema#string